TickerFacts.

Compare

ADMA Biologics, Inc. vs Twist Bioscience Corp vs Repligen Corp vs Adaptive Biotechnologies Corp

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearADMA Biologics, Inc.
ADMA		Twist Bioscience Corp
TWST		Repligen Corp
RGEN		Adaptive Biotechnologies Corp
ADPT
Year ended2025-12-312025-09-302025-12-312025-12-31
Revenue$510.17M$376.57M$738.26M$276.98M
Revenue growth (YoY)+19.6%+20.3%+16.4%+54.8%
Gross margin57.4%50.7% (computed)52.3% (computed)74.2% (computed)
Operating margin37.5%-36.2%7.5%-20.6%
Net margin28.8%-20.6%6.6%-21.5%
Net income$146.93M-$77.67M$48.89M-$59.50M
EPS (Diluted)$0.60-$1.30$0.86-$0.39
Operating cash flow$50.40M-$47.63M$117.42M-$45.99M
Free cash flow$27.82M-$75.63M$93.90M-$48.95M
Cash & equivalents$87.63M$183.05M$566.02M$70.50M
Total assets$624.24M$641.86M$2.95B$512.74M
Total liabilities$146.92M$168.90M$843.57M$287.74M
Shareholders' equity$477.32M$472.96M$2.11B$218.79M
Return on year-end equity30.8%-16.4%2.3%-27.2%
Shares outstanding237.87M60.63M56.33M153.78M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearADMA Biologics, Inc.Twist Bioscience CorpRepligen CorpAdaptive Biotechnologies Corp
Latest$510.17M
Ended 2025-12-31		$376.57M
Ended 2025-09-30		$738.26M
Ended 2025-12-31		$276.98M
Ended 2025-12-31
1 year earlier$426.45M
Ended 2024-12-31		$312.97M
Ended 2024-09-30		$634.44M
Ended 2024-12-31		$178.96M
Ended 2024-12-31
2 years earlier$258.21M
Ended 2023-12-31		$245.11M
Ended 2023-09-30		$632.36M
Ended 2023-12-31		$170.28M
Ended 2023-12-31
3 years earlier$154.08M
Ended 2022-12-31		$203.56M
Ended 2022-09-30		$801.54M
Ended 2022-12-31		$185.31M
Ended 2022-12-31
4 years earlier$80.94M
Ended 2021-12-31		$132.33M
Ended 2021-09-30		$670.53M
Ended 2021-12-31		$154.34M
Ended 2021-12-31